Overview

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

Status:
Completed
Trial end date:
2020-03-05
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.
Phase:
Phase 3
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
Buprenorphine
Naltrexone